News >

Long-Term Data Spark Investigation of Brentuximab Combos in Hodgkin Lymphoma Subgroups

Jessica Hergert
Published: Tuesday, Feb 25, 2020

Ayad Hamdan, MD, a hematologist and an associate professor of medicine at Moores Cancer Center at the University of California, San Diego

Ayad Hamdan, MD

The addition of the antibody-drug conjugate brentuximab vedotin (Adcetris) to the advanced Hodgkin lymphoma treatment paradigm is having a more widespread effect across patient subgroups, said Ayad Hamdan, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication